Table 7.

Overview of the clinical efficacy of dopamine receptor partial agonists (DRPA).

• All DRPAs have evidence of acute antipsychotic efficacy that is comparable: it is lower than in some other AP2G (clozapine, amisulpride, olanzapine, and risperidone)

• All DRPAs have comparable evidence of preventing relapse of schizophrenia

• Aripiprazole (≥15 mg/day) and cariprazine (≥3 mg/day) are effective in acute mania

• Cariprazine (1.5–3 mg/day) is effective in bipolar depression

• Aripiprazole in monotherapy (15–30 mg/day), as addon (10–30 mg/day), or LAI (400 mg/4 weeks) is effective in maintenance treatment of bipolar disorder and for preventing relapse to mania

• Aripiprazole (5–15 mg/day) and brexpiprazole (≥2 mg/day) are effective as adjunctive treatment for major depression with insufficient response

• Cariprazine (4.5 mg/day) is effective in treatment of primary, predominant negative symptoms of schizophrenia

• Aripiprazole i.m. injection (9.75 mg/day) is effective for acute agitation in psychosis or bipolar disorder

• Brexpiprazole (2 mg/day) has potential efficacy in the management of acute agitation in Alzheimer's dementia

• Aripiprazole has evidence of efficacy in other indications: treatment of schizophrenia and bipolar disorder in children and adolescents (10–17 years), clozapine augmentation in refractory schizophrenia, adjunctive treatment of obsessive–compulsive disorder (OCD), tic disorders, and autism spectrum disorders